Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1422142 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $3.66Day −0.54%Mkt cap $181M1Y +106.8%Off 52W high −33.4%Vol (1Y) 78.3%
Daily closing price, split-adjusted to the current basis; 1.3y shown of 332 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.5% of sh out |
| Days to cover7.6d |
| 13F net flow (QoQ)+1.61% |
| Top-10 13F concentration80.3% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$115.8M |
| ROE−21.8% |
| Net margin−288.3% |
| Sales growth 3Y−22.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+51.2% |
| 1Y+106.8% |
| Since incept. (ann.)+54.8% |
Total return through 2026-07-29 · series begins 2025-03-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)78.3% |
| Ann. volatility (3Y)74.7% |
| Sharpe (1Y)1.31 |
| Sharpe (3Y)0.97 |
| Max drawdown (1Y)−28.2% |
| Max drawdown (3Y)−29.3% |
| Beta (3Y vs SPY)1.64 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| QVT Financial LP | 4.6M | $16M | 9.33% | +0.0% |
| ORBIMED ADVISORS LLC | 4.2M | $14M | 8.42% | +0.0% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3.7M | $13M | 7.48% | +0.0% |
| ACUTA CAPITAL PARTNERS, LLC | 3.4M | $12M | 6.90% | +0.0% |
| Avoro Capital Advisors LLC | 2.8M | $10M | 5.76% | +0.0% |
| KVP Capital Advisors, LP | 2.2M | $7M | 4.38% | +0.0% |
| Siren, L.L.C. | 2.1M | $7M | 4.21% | +0.0% |
| Yu Fan | 2.1M | $7M | 4.19% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.32 | −117.5% | $0 | −100.0% |
| 2025-12-31 | 2026-03-12 | — | — | $0 | −100.0% |
| 2025-09-30 | 2025-11-06 | −$0.26 | — | $0 | −100.0% |
| 2025-06-30 | 2025-08-07 | −$0.76 | — | $0 | −100.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
